why choose us

First received: June 09, 2023

Clinical Trial: Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma

Brief Summary: This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment.The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone.Using lower doses of pomalidomide and dexamethasone in this setting has not been approved…

Read more